Ganaxolone treatment for epilepsy patients: from pharmacology to place in therapy

References

• Hirtz D, Thurman DJ, Gwinn-Hardy K, et al. How common are the “common” neurologic disorders? Neurology. 2007;68(5):326–337.
   PubMed Web of Science ®Google Scholar
• Cockerell OC, Johnson AL, Sander JW, et al. Remission of epilepsy: results from the national general practice study of epilepsy. Lancet. 1995;346(8968):140–144.
   PubMed Web of Science ®Google Scholar
• Lattanzi S, Zaccara G, Giovannelli F, et al. Antiepileptic monotherapy in newly diagnosed focal epilepsy. A network meta-analysis. Acta Neurol Scand. 2019;139(1):33–41.
   PubMed Web of Science ®Google Scholar
• Lattanzi S, Trinka E, Del Giovane C, et al. Antiepileptic drug monotherapy for epilepsy in the elderly: a systematic review and network meta-analysis Epilepsia. Epilepsia. 2019;60(11):2245–2254.
   PubMed Web of Science ®Google Scholar
• Chen Z, Brodie MJ, Liew D, et al., Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 75(3): 279–286. 2018. .
   PubMed Web of Science ®Google Scholar
• Lattanzi S, Trinka E, Striano P, et al. Cannabidiol efficacy and clobazam status: a systematic review and meta-analysis. Epilepsia. 2020;61(6):1090–1098.
   PubMed Web of Science ®Google Scholar
• Laxer KD, Trinka E, Hirsch LJ, et al. The consequences of refractory epilepsy and its treatment. Epilepsy Behav. 2014;37:59–70.
   PubMed Web of Science ®Google Scholar
• Lattanzi S, Trinka E, Zaccara G, et al. Adjunctive Cenobamate for focal-onset seizures in adults: a systematic review and meta-analysis. CNS Drugs. 2020;34(11):1105–1120.
   PubMed Web of Science ®Google Scholar
• Mensah-Nyagan A, Do-Rego JL, Beaujean D, et al. Neurosteroids: expression of steroidogenic enzymes and regulation of steroid biosynthesis in the central nervous system. Pharmacol Rev. 1999;51(1):63–81.
   PubMed Web of Science ®Google Scholar
• Miziak B, Chroscinska-Krawczyk M, Czuczwar SJ. Neurosteroids and seizure activity. Front Endocrinol (Lausanne). 2020;11:541802. [ 30].
   PubMed Web of Science ®Google Scholar
• Malayev A, Gibbs TT, Farb DH. Inhibition of the NMDA response by pregnenolone sulphate reveals subtype selective modulation of NMDA receptors by sulphated steroids. Br J Pharmacol. 2002;135(4):901–909.
   PubMed Web of Science ®Google Scholar
• Wu FS, Gibbs TT, Farb DH. Pregnenolone sulfate: a positive allosteric modulator at the N-methyl-D-aspartate receptor. Mol Pharmacol. 1991;40(3):333–336.
   PubMed Web of Science ®Google Scholar
• Horishita T, Minami K, Uezono Y, et al. The effects of the neurosteroids: pregnenolone, progesterone and dehydroepiandrosterone on muscarinic receptor-induced responses in Xenopus oocytes expressing M1 and M3 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2005;371(3):221–228.
   PubMed Web of Science ®Google Scholar
• Bullock AE, Clark AL, Grady SR, et al. Neurosteroids modulate nicotinic receptor function in mouse striatal and thalamic synaptosomes. J Neurochem. 1997;68(6):2412–2423.
   PubMed Web of Science ®Google Scholar
• Maksay GB, Laube H, Betz H. Subunit-specific modulation of glycine receptors by neurosteroids. Neuropharmacology. 2001;41(3):369–376.
   PubMed Web of Science ®Google Scholar
• Schumacher M, Mattern C, Ghoumari A, et al. Revisiting the roles of progesterone and allopregnanolone in the nervous system: resurgence of the progesterone receptors. Prog Neurobiol. 2014;113:6–39.
   PubMed Web of Science ®Google Scholar
• Biagini G, Panuccio G, Avoli M. Neurosteroids and epilepsy. Curr Opin Neurol. 2010;23(2):170–176.
   PubMed Web of Science ®Google Scholar
• Hosie AD, Wilkins ME, Da Silva HMA, et al., Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites. Nature. 444(7118): 486–489. 2006. .
   PubMed Web of Science ®Google Scholar
• Reddy DS, Rogawski MA. Neurosteroid replacement therapy for catamenial epilepsy. Neurotherapeutics. 2009;6(2):392–401.
   PubMed Web of Science ®Google Scholar
• Monaghan EP, McAuley JW, Data JL. Ganaxolone: a novel positive allosteric modulator of the GABA(A) receptor complex for the treatment of epilepsy. Expert Opin Investig Drugs. 1999;8(10):1663–1671.
   PubMedGoogle Scholar
• Turkmen S, Backstrom T, Wahlstrom G, et al. Tolerance to allopregnanolone with focus on the GABA-A receptor. Br J Pharmacol. 2011;162(2):311–327.
   PubMed Web of Science ®Google Scholar
• Carter RB, Wood PL, Wieland S, et al. Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid(A) receptor. J Pharmacol Exp Ther. 1997;280(3):1284–1295.
   PubMed Web of Science ®Google Scholar
• Nohria V, Giller E. Ganaxolone. Neurotherapeutics. 2007;4(1):102–105.
   PubMed Web of Science ®Google Scholar
• Nik AM, Pressly B, Singh V, et al. Rapid throughput analysis of GABA A receptor subtype modulators and blockers using DiSBAC1(3) Membrane Potential Red Dye. Mol Pharmacol. 2017;92(1):88–99.
   PubMed Web of Science ®Google Scholar
• Gasior M, Carter RB, Goldberg SR, et al. Anticonvulsant and behavioral effects of neuroactive steroids alone and in conjunction with diazepam. J Pharmacol Exp Ther. 1997;282(2):543–553.
   PubMed Web of Science ®Google Scholar
• Beekman M, Ungard JT, Gasior M, et al. Reversal of behavioral effects of pentylenetetrazol by the neuroactive steroid ganaxolone. J Pharmacol Exp Ther. 1998;284(3):868–877.
   PubMed Web of Science ®Google Scholar
• Snead OC. 3rd. Ganaxolone, a selective, high-affinity steroid modulator of the gamma-aminobutyric acid-A receptor, exacerbates seizures in animal models of absence. Ann Neurol. 1998;44(4):688–691.
   PubMed Web of Science ®Google Scholar
• Gasior M, Ungard JT, Beekman M, et al. Acute and chronic effects of the synthetic neuroactive steroid, ganaxolone, against the convulsive and lethal effects of pentylenetetrazol in seizure-kindled mice: comparison with diazepam and valproate. Neuropharmacology. 2000;39(7):1184–1196.
   PubMed Web of Science ®Google Scholar
• Liptáková S, Velísek L, Velísková J, et al. Effect of ganaxolone on flurothyl seizures in developing rats. Epilepsia. 2000;41(7):788–793.
   PubMed Web of Science ®Google Scholar
• Reddy DS, Rogawski MA. Enhanced anticonvulsant activity of ganaxolone after neurosteroid withdrawal in a rat model of catamenial epilepsy. J Pharmacol Exp Ther. 2000;294(3):909–915.
   PubMed Web of Science ®Google Scholar
• Reddy DS, Rogawski MA. Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself. J Pharmacol Exp Ther. 2000;295(3):1241–1248.
   PubMed Web of Science ®Google Scholar
• Kaminski RM, Gasior M, Carter RB, et al. Protective efficacy of neuroactive steroids against cocaine kindled-seizures in mice. Eur J Pharmacol. 2003;474(2–3):217–222.
   PubMed Web of Science ®Google Scholar
• Kaminski RM, Livingood MR, Rogawski MA. Allopregnanolone analogs that positively modulate GABA receptors protect against partial seizures induced by 6-Hz electrical stimulation in mice. Epilepsia. 2004;45(7):864–867.
   PubMed Web of Science ®Google Scholar
• Citraro R, Russo E, Di Paola ED, et al. Effects of some neurosteroids injected into some brain areas of WAG/Rij rats, an animal model of generalized absence epilepsy. Neuropharmacology. 2006;50(8):1059–1071.
   PubMed Web of Science ®Google Scholar
• Mares P, Kubová H, Kasal A. Anticonvulsant action of a new analogue of allopregnanolone in immature rats. Physiol Res. 2010;59:305–308.
   PubMed Web of Science ®Google Scholar
• Mares P, Stehlíková M. Anticonvulsant doses of ganaxolone do not compromise motor performance in immature rats. Neurosci Lett. 2010;469(3):396–399.
   PubMed Web of Science ®Google Scholar
• Reddy DS, Rogawski MA. Ganaxolone suppression of behavioral and electrographic seizures in the mouse amygdala kindling model. Epilepsy Res. 2010;89(2–3):254–260.
   PubMed Web of Science ®Google Scholar
• Yum MS, Lee M, Ko TS, et al. A potential effect of ganaxolone in an animal model of infantile spasms. Epilepsy Res. 2014;108(9):1492–1500.
   PubMed Web of Science ®Google Scholar
• Ciarlone SL, Wang X, Rogawski MA, et al. Effects of the synthetic neurosteroid ganaxolone on seizure activity and behavioral deficits in an Angelman syndrome mouse model. Neuropharmacology. 2017;116:142–150.
   PubMed Web of Science ®Google Scholar
• Zolkowska D, Wu CY, Rogawski MA. Intramuscular allopregnanolone and ganaxolone in a mouse model of treatment-resistant status epilepticus. Epilepsia. 2018;59(Suppl 2):220–227.
   PubMedGoogle Scholar
• Reddy DS, Yoshimura RF, Ramanathan G, et al. Role of ß 2/3-specific GABA-A receptor isoforms in the development of hippocampus kindling epileptogenesis. Epilepsy Behav. 2018;82:57–63.
   PubMed Web of Science ®Google Scholar
• Saporito MS, Gruner JA, DiCamillo A, et al. Intravenously administered ganaxolone blocks diazepam-resistant lithium-pilocarpine-induced status epilepticus in rats: comparison with allopregnanolone. J Pharmacol Exp Ther. 2019;368(3):326–337.
   PubMed Web of Science ®Google Scholar
• Reddy DS, Carver CM, Clossen B, et al. Extrasynaptic ?-aminobutyric acid type A receptor-mediated sex differences in the antiseizure activity of neurosteroids in status epilepticus and complex partial seizures. Epilepsia. 2019;60(4):730–743.
   PubMed Web of Science ®Google Scholar
• Barker BS, Spampanato J, McCarren HS, et al. Screening for efficacious anticonvulsants and neuroprotectants in delayed treatment models of organophosphate-induced status epilepticus. Neuroscience. 2020;425:280–300.
   PubMed Web of Science ®Google Scholar
• Chuang SH, Reddy DS. Isobolographic analysis of antiseizure activity of the GABA type A Receptor-modulating synthetic neurosteroids brexanolone and ganaxolone with tiagabine and midazolam. J Pharmacol Exp Ther. 2020;372(3):285–298.
   PubMed Web of Science ®Google Scholar
• Cagnetti C, Lattanzi S, Foschi N, et al. Seizure course during pregnancy in catamenial epilepsy. Neurology. 2014;83(4):339–344.
   PubMed Web of Science ®Google Scholar
• Coenen AM, Van Luijtelaar EL. Genetic animal models for absence epilepsy: a review of the WAG/Rij strain of rats. Behav Genet. 2003;33(6):635–655.
   PubMed Web of Science ®Google Scholar
• D’Antuono M, Inaba Y, Biagini G, et al. Synaptic hyperexcitability of deep layer neocortical cells in a genetic model of absence seizures. Genes Brain Behav. 2006;5(1):73–84.
   PubMed Web of Science ®Google Scholar
• Naylor DE, Liu H, Wasterlain CG. Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus. J Neurosci. 2005;25(34):7724–7733.
   PubMed Web of Science ®Google Scholar
• Meletti S, Lucchi C, Monti G, et al. Low levels of progesterone and derivatives in cerebrospinal fluid of patients affected by status epilepticus. J Neurochem. 2018;147(2):275–284.
   PubMed Web of Science ®Google Scholar
• Monaghan EP, Navalta LA, Shum L, et al. Initial human experience with ganaxolone, a neuroactive steroid with antiepileptic activity. Epilepsia. 1997;38(9):1026–1031.
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Koepp MJ, et al. Progress report on new antiepileptic drugs: a summary of the Fifteenth Eilat conference on new antiepileptic drugs and devices (EILAT XV). II. Drugs in more advanced clinical development. Epilepsia. 2020;61:2365–2385.
   Google Scholar
• Zaccara G, Schmidt D. Do traditional anti-seizure drugs have a future? A review of potential antiseizure drugs in clinical development. Pharmacol Res. 2016;104:38–48.
   PubMed Web of Science ®Google Scholar
• Ram K, Lam GN, Chien B. A high-performance liquid chromatography-tandem mass spectrometric method for the determination of pharmacokinetics of ganaxolone in rat, monkey, dog and human plasma. J Chromatogr B Biomed Sci Appl. 2001;751(1):49–59.
   PubMed Web of Science ®Google Scholar
• Younus I, Reddy DS. A resurging boom in new drugs for epilepsy and brain disorders. Expert Rev Clin Pharmacol. 2018;11(1):27–45.
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the thirteenth eilat conference on new antiepileptic drugs and devices (EILAT XIII). Epilepsia. 2017;58(2):181–221.
   PubMed Web of Science ®Google Scholar
• Laxer K, Blum D, Abou-Khalil BW, et al. Assessment of ganaxolone’s anticonvulsant activity using a randomized, double-blind, presurgical trial design. Ganaxolone Presurgical Study Group. Epilepsia. 2000;41(9):1187–1194.
   PubMed Web of Science ®Google Scholar
• Sperling MR, Klein P, Tsai J. Randomized, double-blind, placebo-controlled phase 2 study of ganaxolone as add-on therapy in adults with uncontrolled partial-onset seizures. Epilepsia. 2017;58(4):558–564.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Open-label extension to protocol 1042-0600. Available from: https://clinicaltrials.gov/ct2/show/NCT00512317. cited Jan 2021.
   Google Scholar
• ClinicalTrials.gov. A treatment use protocol for subjects continuing on from the open-label extension 0601. Available from: https://clinicaltrials.gov/ct2/show/NCT01002820. cited Jan 2021.
   Google Scholar
• Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Twelfth Eilat Conference (EILAT XII). Epilepsy Res. 2015;111:85–141.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Phase 3 study of adjunctive ganaxolone in adults with drug-resistant partial onset seizures and open-label extension. Available from: https://clinicaltrials.gov/ct2/show/NCT01963208. cited Jan 2021.
   Google Scholar
• ClinicalTrials.gov. A two-year open-label extension study of ganaxolone in patients with drug-resistant partial-onset seizures. Available from: https://clinicaltrials.gov/ct2/show/NCT02519439. cited Jan 2021.
   Google Scholar
• Bialer M, Johannessen SI, Koepp M, et al. Progress report on new antiepileptic drugs: a summary of the fourteenth eilat conference on new antiepileptic drugs and devices (EILAT XIV). II. Drugs in more advanced clinical development. Epilepsia. 2018;59:1842–1866.
   Google Scholar
• Lappalainen J, Tsai J, Amerine W, et al. A multicenter, double blind, randomized, placebo-controlled phase 3 trial to determine the efficacy and safety of ganaxolone as adjunctive therapy for adults with drug-resistant focal-onset seizures. Neurology. 2017;88(16 Suppl):237.
   PubMedGoogle Scholar
• Pavone P, Striano P, Falsaperla R, et al. Infantile spasms syndrome, West syndrome and related phenotypes: what we know in 2013. Brain Dev. 2014;36(9):739–751.
   PubMed Web of Science ®Google Scholar
• Calvo A, Buompadre MC, Gallo A, et al. Electroclinical pattern in the transition from West to Lennox-Gastaut syndrome. Epilepsy Res. 2020;167:106446.
   PubMed Web of Science ®Google Scholar
• O’Callaghan FJK, Edwards SW, Alber FD, et al. Vigabatrin with hormonal treatment versus hormonal treatment alone (ICISS) for infantile spams: 18-month outcomes of an open-label, randomised controlled trial. Lancet Child Adolesc Health. 2018;2(10):715–725.
   PubMedGoogle Scholar
• Valdez JM. [Transitional syndrome: from West to Lennox-Gastaut syndromes]. Medicina (B Aires). 2018;78(Suppl 2): 2–5. (abstract).
   PubMedGoogle Scholar
• Pieribone VA, Tsai J, Soufflet C, et al. Clinical evaluation of ganaxolone in pediatric and adolescent patients with refractory epilepsy. Epilepsia. 2007;4(10):1870–1874.
   Google Scholar
• Kerrigan JF, Shields WD, Nelson TY, et al. Ganaxolone for treating intractable infantile spasms: a multicenter, open-label, add-on trial. Epilepsy Res. 2000;42(2–3):133–139.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A randomized, controlled trial of ganaxolone in patients with infantile spasms. Available from: https://clinicaltrials.gov/ct2/show/NCT00441896. cited Jan 2021.
   Google Scholar
• Giordano C, Marchiã² M, Timofeeva E, et al. Neuroactive peptides as putative mediators of antiepileptic ketogenic diets. Front Neurol. 2014;5:63.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Open-label Extension to Protocol 1042-0500. Available from: https://clinicaltrials.gov/ct2/show/NCT00442104. cited Jan 2021.
   Google Scholar
• Joshi S, Kapur J. Neurosteroid regulation of GABA(A) receptors: a role in catamenial epilepsy. Brain Res. 2019;1703:31–40.
   PubMed Web of Science ®Google Scholar
• Pugnaghi M, Monti G, Biagini G, et al. Temporal lobe epilepsy exacerbation during pharmacological inhibition of endogenous neurosteroid synthesis. BMJ Case Rep. 2013;2013:bcr2012008204.
   PubMedGoogle Scholar
• Melcangi RC, Celotti F, Martini L. Progesterone 5-alpha-reduction in neuronal and in different types of glial cell cultures: type 1 and 2 astrocytes and oligodendrocytes. Brain Res. 1994;639(2):202–206.
   PubMed Web of Science ®Google Scholar
• Avallone R, Lucchi C, Puja G, et al. BV-2 Microglial Cells Respond to rotenone toxic insult by modifying pregnenolone, 5a-dihydroprogesterone and pregnanolone levels. Cells. 2020;9(9):2091.
   Web of Science ®Google Scholar
• Reddy DS. Perimenstrual catamenial epilepsy. Womens Health (Lond). 2007;3(2):195–206.
   PubMedGoogle Scholar
• McAuley JW, Moore JL, Reeves AL, et al. A pilot study of the neurosteroid ganaxolone in catamenial epilepsy: clinical experience in two patients. Epilepsia. 2001;42(Suppl 7):85. (abstract).
   Google Scholar
• Curatolo P, Moavero R, De Vries PJ. Neurological and neuropsychiatric aspects of tuberous sclerosis complex. Lancet Neurol. 2015;14(7):733–745.
   PubMed Web of Science ®Google Scholar
• O’Callaghan FJ, Shiell AW, Osborne JP, et al. Prevalence of tuberous sclerosis estimated by capture-recapture analysis. Lancet. 1998;351(9114):1490.
   PubMed Web of Science ®Google Scholar
• Saxena A, Sampson JR. Epilepsy in tuberous sclerosis: phenotypes, mechanisms, and treatments. Semin Neurol. 2015;35(3):269–276.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Adjunctive Ganaxolone treatment (Part A) in TSC followed by long-term treatment (Part B). Available from: https://clinicaltrials.gov/ct2/show/NCT04285346. cited Jan 2021.
   Google Scholar
• Olson HE, Demarest ST, Pestana-Knight EM. Cyclin-dependent kinase-like 5 deficiency disorder: clinical review. Pediatr Neurol. 2019;97:18–25.
   PubMed Web of Science ®Google Scholar
• Zhu YC, Xionh ZQ. Molecular and synaptic bases of CDKL5 disorder. Dev Neurobiol. 2019;79(1):8–19.
   PubMed Web of Science ®Google Scholar
• Müller A, Helbig I, Jansen C, et al. Retrospective evaluation of low long-term efficacy of antiepileptic drugs and ketogenic diet in 39 patients with CDKL5-related epilepsy. Eur J Paediatr Neurol. 2016;20(1):147–151.
   PubMed Web of Science ®Google Scholar
• Pestana-Knight E, Amin S, Cross JH, et al. Ganaxolone significantly reduces major motor seizures associated with CDKL5 deficiency disorder: a randomized, double-blind, placebo-controlled phase 3 study (Marigold study). The American Epilepsy Society Annual Meeting; Virtual; 4-8 December, 2021. Abstract 419. Available at: https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/2422763. cited Jan 2021.
   Google Scholar
• Pestana-Knight EM, Aimetti A, Hulihan J Effect of ganaxolone on seizure frequency across subpopulations of patients with CDKL5 deficiency disorder: subgroup analyses of the Marigold study. The American Epilepsy Society Annual Meeting; Virtual; 4-8 December, 2021. Abstract 419. Available at: https://marinuspharma.com/wp-content/uploads/2020/12/Ganaxolone_Subgroup_Poster_111820a_FINAL.pdf. cited Jan 2021.
   Google Scholar
• Hulihan J, Li D, Aimetti A Pharmacokinetic-pharmacodynamic analysis in ganaxolone-treated patients with CDKL5 deficiency disorder: results from the Marigold study. The American Epilepsy Society Annual Meeting; Virtual; 4-8 December, 2021. Available at: https://marinuspharma.com/wp-content/uploads/2020/12/Hulihan_PKPD_Poster_111720b_FINAL.pdf. cited Jan 2021.
   Google Scholar
• Specchio N, Amin S, Aimetti A, et al. Extended duration safety and efficacy of ganaxolone for the treatment of CDKL5 deficiency disorder: preliminary open-label extension analysis (Marigold study). The American Epilepsy Society Annual Meeting; Virtual; 4-8 December, 2021. Available at: https://marinuspharma.com/wp-content/uploads/2020/12/5_AES2020_Marigold-Prelim-OpenLabel-Analysis.pdf. cited Jan 2021.
   Google Scholar
• Serratto GM, Pizzi E, Murru L, et al. The epilepsy-related protein PCDH19 Regulates tonic inhibition, GABAAR kinetics, and the intrinsic excitability of hippocampal neurons. Mol Neurobiol. 2020;57(12):5336–5351.
   PubMed Web of Science ®Google Scholar
• Samanta D. PCDH19-related epilepsy syndrome: a comprehensive clinical review. Pediatr Neurol. 2020;105:3–9.
   PubMed Web of Science ®Google Scholar
• Depienne C, LeGuern E. PCDH19 related infantile epileptic encephalopathy: an unusual X-linked inheritance disorder. Hum Mutat. 2012;33(4):627–634.
   PubMed Web of Science ®Google Scholar
• Tan C, Shard C, Ranieri E, et al. Mutations of protocadherin 19 in female epilepsy (PCDH19-FE) lead to allopregnanolone deficiency. Hum Mol Genet. 2015;24(18):5250–5259.
   PubMed Web of Science ®Google Scholar
• Trivisano M, Lucchi C, Rustichelli C, et al. Reduced steroidogenesis in patients with PCDH19-female limited epilepsy Epilepsia. Epilepsia. 2017;58(6):e91–5.
   PubMed Web of Science ®Google Scholar
• Sullivan J, Specchio N, Chez MG, et al. Preliminary evidence of a predictive clinical biomarker in PCDH19-related epilepsy: significant treatment effect of ganaxolone in biomarker-positive patients. The American Epilepsy Society Annual Meeting; New Orleans, Louisiana; November 30-December 4, 2018. Abstract 2.251. Available at: https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/502507. cited Jan 2021.
   Google Scholar
• ClinicalTrials.gov. Study of adjunctive ganaxolone treatment in female children with protocadherin 19 (PCDH19)-related epilepsy (violet study) Available from: https://clinicaltrials.gov/ct2/show/NCT03865732. cited Jan 2021.
   Google Scholar
• Riva A, Iapadre G, Grasso EA, et al. Intramuscular midazolam for treatment of status epilepticus. Expert Opin Pharmacother. 2021;22(1):37–44.
   PubMed Web of Science ®Google Scholar
• Brigo F, Bragazzi NL, Lattanzi S, et al. A critical appraisal of randomized controlled trials on intravenous phenytoin in convulsive status epilepticus. Eur J Neurol. 2018;25(3):451–463.
   PubMed Web of Science ®Google Scholar
• Brigo F, Del Giovane C, Nardone R, et al. Intravenous antiepileptic drugs in adults with benzodiazepine-resistant convulsive status epilepticus: a systematic review and network meta-analysis. Epilepsy Behav. 2019;101(Pt B):106466.
   PubMedGoogle Scholar
• Brigo F, Lattanzi S, Rohracher A, et al. Perampanel in the treatment of status epilepticus: a systematic review of the literature. Epilepsy Behav. 2018;86:179–186.
   PubMed Web of Science ®Google Scholar
• Brigo F, Lattanzi S, Nardone R, et al. Intravenous brivaracetam in the treatment of status epilepticus: a systematic review. CNS Drugs. 2019;33(8):771–781.
   PubMed Web of Science ®Google Scholar
• Husain AM, Swisher CB, Ramsay E, et al. Intravenous ganaxolone achieves rapid and dose-dependent sustained improvement in EEG seizure burden in patients with refractory status epilepticus”. The American Clinical Neurophysiology Society Annual Meeting; New Orleans, Louisiana; February 5-9, 2020. Abstract 793677. Available at: https://marinuspharma.com/wp-content/uploads/2020/09/ACN2020-EEG-Seizure-Burden_vFINAL.pdf. cited Jan 2021.
   Google Scholar
• ClinicalTrials.gov. RAndomized Therapy In Status Epilepticus. Available from: https://clinicaltrials.gov/ct2/show/NCT04391569. cited Jan 2021.
   Google Scholar
• Ungard JT, Beekman M, Gasior M, et al. Modification of behavioral effects of drugs in mice by neuroactive steroids. Psychopharmacology (Berl). 2000;148(4):336–343.
   PubMed Web of Science ®Google Scholar
• Robichaud M, Debonnel G. Allopregnanolone and ganaxolone increase the firing activity of dorsal raphe nucleus serotonergic neurons in female rats. Int J Neuropsychopharmacol. 2006;9(2):191–200.
   PubMed Web of Science ®Google Scholar
• Dichtel LE, Nyer M, Dording C, et al. Effects of open-label, adjunctive ganaxolone on persistent depression despite adequate antidepressant treatment in postmenopausal women: a pilot study. J Clin Psychiatry. 2020;81(4):19m12887.
   PubMed Web of Science ®Google Scholar
• Pinna G, Rasmusson AM. Ganaxolone improves behavioral deficits in a mouse model of post-traumatic stress disorder. Front Cell Neurosci. 2014;8:256.
   PubMed Web of Science ®Google Scholar
• Pinna G. Targeting neurosteroidogenesis as therapy for PTSD. Front Pharmacol. 2014;4:166.
   PubMed Web of Science ®Google Scholar
• Rasmusson AM, Marx CE, Jain S, et al. A randomized controlled trial of ganaxolone in posttraumatic stress disorder. Psychopharmacology (Berl). 2017;234(15):2245–2257.
   PubMed Web of Science ®Google Scholar
• Ramaker MJ, Ford MM, Fretwell AM, et al. Alteration of ethanol drinking in mice via modulation of the GABA(A) receptor with ganaxolone, finasteride, and gaboxadol. Alcohol Clin Exp Res. 2011;35(11):1994–2007.
   PubMed Web of Science ®Google Scholar
• Besheer J, Lindsay TG, Buckley TO, et al. Pregnenolone and ganaxolone reduce operant ethanol self-administration in alcohol-preferring p rats. Alcohol Clin Exp Res. 2010;34(12):2044–2052.
   PubMed Web of Science ®Google Scholar
• Ramaker MJ, Strong MN, Ford MM, et al. Effect of ganaxolone and THIP on operant and limited-access ethanol self-administration. Neuropharmacology. 2012;63(4):555–564.
   PubMed Web of Science ®Google Scholar
• Ramaker MJ, Ford MM, Phillips TJ, et al. Differences in the reinstatement of ethanol seeking with ganaxolone and gaboxadol. Neuroscience. 2014;272:180–187.
   PubMed Web of Science ®Google Scholar
• Sharawat IK, Panda PK, Kasinathan A, et al. Efficacy and tolerability of fenfluramine in patients with Dravet syndrome: a systematic review and meta-analysis. Seizure. 2021;85:119–126.
   PubMed Web of Science ®Google Scholar
• Frampton JE. Stiripentol: a review in Dravet syndrome. Drugs. 2019;79(16):1785–1796.
   PubMed Web of Science ®Google Scholar
• Lattanzi S, Brigo F, Trinka E, et al. Adjunctive cannabidiol in patients with Dravet syndrome: a systematic review and meta-analysis of efficacy and safety. CNS Drugs. 2020;34(3):229–241.
   PubMed Web of Science ®Google Scholar
• Lattanzi S, Brigo F, Cagnetti C, et al. Efficacy and safety of adjunctive cannabidiol in patients with lennox-gastaut syndrome: a systematic review and meta-analysis. CNS Drugs. 2018;32(10):905–916.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Ganaxolone Expanded Access Program Compassionate Use (CDD). Available from: https://clinicaltrials.gov/ct2/show/NCT04678479. cited Jan 2021.
   Google Scholar
• Mitchell RJ, Herkes G, Nikpour A, et al. Examining health service utilization, hospital treatment cost, and mortality of individuals with epilepsy and status epilepticus in New South Wales, Australia 2012-2016. Epilepsy Behav. 2018;79:9–16.
   PubMed Web of Science ®Google Scholar